Exact Mass: 453.1393
Exact Mass Matches: 453.1393
Found 338 metabolites which its exact mass value is equals to given mass value 453.1393
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Danofloxacin Mesylate
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic
Temafloxacin hydrochloride
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors
Benzoic acid, 2,6-bis[(4,6-dimethoxy-2-pyrimidinyl)oxy]-, sodium salt (1:1)
O-Methyl-4-[(2',3',4'-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]carbamate
O-Methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]carbamate is a fully acetylated carbamate glycoside. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables. The trans and cis rotamers differ in the orientation of the NH group with respect to the carbonyl group.
Endoxifen sulfate
Endoxifen sulfate is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
k-252b
7-Hydroxyfluphenazine
3-Amino-6-{4-[(4-Methylpiperazin-1-Yl)sulfonyl]phenyl}-N-Pyridin-3-Ylpyrazine-2-Carboxamide
Fluphenazine sulfoxide
K252b
D004791 - Enzyme Inhibitors
Ala Cys Phe Asn
Ala Cys Asn Phe
Ala Phe Cys Asn
Ala Phe Asn Cys
Ala Asn Cys Phe
Ala Asn Phe Cys
Ala Asn Ser Tyr
Ala Asn Tyr Ser
Ala Ser Asn Tyr
Ala Ser Tyr Asn
Ala Tyr Asn Ser
Ala Tyr Ser Asn
Cys Ala Phe Asn
Cys Ala Asn Phe
Cys Cys Asp Asn
Cys Cys Lys Thr
Cys Cys Asn Asp
Cys Cys Gln Thr
Cys Cys Thr Lys
Cys Cys Thr Gln
Cys Asp Cys Asn
Cys Asp Asn Cys
Cys Phe Ala Asn
Cys Phe Gly Gln
Cys Phe Asn Ala
Cys Phe Gln Gly
Cys Gly Phe Gln
Cys Gly Gln Phe
Cys Lys Cys Thr
Cys Lys Thr Cys
Cys Met Asn Ser
Cys Met Ser Asn
Cys Asn Ala Phe
Cys Asn Cys Asp
Cys Asn Asp Cys
Cys Asn Phe Ala
Cys Asn Met Ser
Cys Asn Ser Met
Cys Gln Cys Thr
Cys Gln Phe Gly
Cys Gln Gly Phe
Cys Gln Thr Cys
Cys Ser Met Asn
Cys Ser Asn Met
Cys Thr Cys Lys
Cys Thr Cys Gln
Cys Thr Lys Cys
Cys Thr Gln Cys
Asp Cys Cys Asn
Asp Cys Asn Cys
Asp Asn Cys Cys
Phe Ala Cys Asn
Phe Ala Asn Cys
Phe Cys Ala Asn
Phe Cys Gly Gln
Phe Cys Asn Ala
Phe Cys Gln Gly
Phe Gly Cys Gln
Phe Gly Gln Cys
Phe Asn Ala Cys
Phe Asn Cys Ala
Phe Asn Ser Ser
Phe Gln Cys Gly
Phe Gln Gly Cys
Phe Ser Asn Ser
Phe Ser Ser Asn
Gly Cys Phe Gln
Gly Cys Gln Phe
Gly Phe Cys Gln
Gly Phe Gln Cys
Gly Asn Thr Tyr
Gly Asn Tyr Thr
Gly Gln Cys Phe
Gly Gln Phe Cys
Gly Gln Ser Tyr
Gly Gln Tyr Ser
Gly Ser Gln Tyr
Gly Ser Tyr Gln
Gly Thr Asn Tyr
Gly Thr Tyr Asn
Gly Tyr Asn Thr
Gly Tyr Gln Ser
Gly Tyr Ser Gln
Gly Tyr Thr Asn
Lys Cys Cys Thr
Lys Cys Thr Cys
Lys Thr Cys Cys
Met Cys Asn Ser
Met Cys Ser Asn
Met Asn Cys Ser
Met Asn Ser Cys
Met Ser Cys Asn
Met Ser Asn Cys
Asn Ala Cys Phe
Asn Ala Phe Cys
Asn Ala Ser Tyr
Asn Ala Tyr Ser
Asn Cys Ala Phe
Asn Cys Cys Asp
Asn Cys Asp Cys
Asn Cys Phe Ala
Asn Cys Met Ser
Asn Cys Ser Met
Asn Asp Cys Cys
Asn Phe Ala Cys
Asn Phe Cys Ala
Asn Phe Ser Ser
Asn Gly Thr Tyr
Asn Gly Tyr Thr
Asn Met Cys Ser
Asn Met Ser Cys
Asn Ser Ala Tyr
Asn Ser Cys Met
Asn Ser Phe Ser
Asn Ser Met Cys
Asn Ser Ser Phe
Asn Ser Tyr Ala
Asn Thr Gly Tyr
Asn Thr Tyr Gly
Asn Tyr Ala Ser
Asn Tyr Gly Thr
Asn Tyr Ser Ala
Asn Tyr Thr Gly
Gln Cys Cys Thr
Gln Cys Phe Gly
Gln Cys Gly Phe
Gln Cys Thr Cys
Gln Phe Cys Gly
Gln Phe Gly Cys
Gln Gly Cys Phe
Gln Gly Phe Cys
Gln Gly Ser Tyr
Gln Gly Tyr Ser
Gln Ser Gly Tyr
Gln Ser Tyr Gly
Gln Thr Cys Cys
Gln Tyr Gly Ser
Gln Tyr Ser Gly
Ser Ala Asn Tyr
Ser Ala Tyr Asn
Ser Cys Met Asn
Ser Cys Asn Met
Ser Phe Asn Ser
Ser Phe Ser Asn
Ser Gly Gln Tyr
Ser Gly Tyr Gln
Ser Met Cys Asn
Ser Met Asn Cys
Ser Asn Ala Tyr
Ser Asn Cys Met
Ser Asn Phe Ser
Ser Asn Met Cys
Ser Asn Ser Phe
Ser Asn Tyr Ala
Ser Gln Gly Tyr
Ser Gln Tyr Gly
Ser Ser Phe Asn
Ser Ser Asn Phe
Ser Tyr Ala Asn
Ser Tyr Gly Gln
Ser Tyr Asn Ala
Ser Tyr Gln Gly
Thr Cys Cys Lys
Thr Cys Cys Gln
Thr Cys Lys Cys
Thr Cys Gln Cys
Thr Gly Asn Tyr
Thr Gly Tyr Asn
Thr Lys Cys Cys
Thr Asn Gly Tyr
Thr Asn Tyr Gly
Thr Gln Cys Cys
Thr Tyr Gly Asn
Thr Tyr Asn Gly
Tyr Ala Asn Ser
Tyr Ala Ser Asn
Tyr Gly Asn Thr
Tyr Gly Gln Ser
Tyr Gly Ser Gln
Tyr Gly Thr Asn
Tyr Asn Ala Ser
Tyr Asn Gly Thr
Tyr Asn Ser Ala
Tyr Asn Thr Gly
Tyr Gln Gly Ser
Tyr Gln Ser Gly
Tyr Ser Ala Asn
Tyr Ser Gly Gln
Tyr Ser Asn Ala
Tyr Ser Gln Gly
Tyr Thr Gly Asn
Tyr Thr Asn Gly
Fluphenazine (further oxidation of piperazine ring)
1-isobutanol
butyl N-[4-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)thiophen-2-yl]sulfonylcarbamate
L-Norleucine, L-g-glutamyl-6-diazo-5-oxo-L-norleucyl-6-diazo-5-oxo-
4-METHOXYPHENYL-2-ACETAMIDO-3,4,6-TRI-O-ACETYL-2-DEOXY-BETA-D-GLUCOPYRANOSIDE
tetraethyl 2-(4-nitrophenyl)propane-1,1,3,3-tetracarboxylate
(2S,4S)-4-Diphenylphosphino 2-diphenylphosphinomethyl pyrrolidine
2-[[4-[(2-cyano-3-nitrophenyl)azo]-m-tolyl](2-acetoxyethyl)amino]ethyl acetate
dimethyl 5-[[1-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]carbonyl]-2-oxopropyl]azoterephthalate
4-[4-[4-(AMINOIMINOMETHYL)PHENYL]-1-PIPERAZINYL]-1-PIPERIDINEACETIC ACID TRIHYDROCHLORIDE
methyl 5-chloro-2-[(4-ethoxy-4-oxobutyl)-(4-methylphenyl)sulfonylamino]benzoate
dimethyl 2-[[1-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]carbonyl]-2-oxopropyl]azo]terephthalate
Vodobatinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Oclacitinib maleate
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
Axitirome
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
N-[4-amino-1-(2-chloroethyl)-2-naphthyl]-5,6,7-trimethoxy-1H-indole-2-carboxamide
Thieno[3,2-B]pyridine-2-sulfonic acid [1-(1-amino-isoquinolin-7-ylmethyl)-2-oxo-pyrroldin-3-YL]-amide
N-[5-(1,1-Dioxidoisothiazolidin-2-YL)-1H-indazol-3-YL]-2-(4-piperidin-1-ylphenyl)acetamide
(2s,3s)-3-{3-[2-Chloro-4-(Methylsulfonyl)phenyl]-1,2,4-Oxadiazol-5-Yl}-1-Cyclopentylidene-4-Cyclopropyl-1-Fluorobutan-2-Amine
[4,5-Diacetyloxy-6-[4-[(methoxycarbonylamino)methyl]phenoxy]-2-methyloxan-3-yl] acetate
[(1R,2R,3R,4S)-1-acetyloxy-2,4-dihydroxy-11-methanimidoyl-2-methyl-5,9,10-trioxo-1,3,4,6-tetrahydrobenzo[b]fluoren-4b-ylium-6-id-3-yl] acetate
N-[2-(2-methyl-1H-indol-3-yl)ethyl]-1-nitro-9,10-dioxo-2-anthracenecarboxamide
4-[4-(2,3,5,6-tetramethylphenyl)sulfonylpiperazine-1-carbonyl]-1H-quinolin-2-one
3-[[2-[[4-Ethyl-5-[(4-methylanilino)methyl]-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]benzoic acid ethyl ester
N-[[5-(1,3-benzothiazol-2-yl)-2-methylanilino]-sulfanylidenemethyl]-1-naphthalenecarboxamide
1-(3-chlorophenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea
Ethyl 4-oxo-4-[(18-phenyl-11-oxa-13,15-diazatetracyclo[8.8.0.02,7.012,17]octadeca-1(10),2,4,6,8,12,14,16-octaen-16-yl)amino]butanoate
N-benzoylampicillin
A penicillin that is the N-benzoyl derivative of ampicillin.
[2-Methyl-1-(2-phenylethyl)-3-imidazo[1,2-a]pyridin-4-iumyl]-diphenyl-sulfanylidenephosphorane
CID 23724790
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
Methyl (1S,3S,4R,7R,9R,11S,12S,13S)-5-(6-aminopurin-9-yl)-1,12,13-trihydroxy-4-methoxy-2,6,10-trioxatricyclo[7.4.0.03,7]tridecane-11-carboxylate
2-[(3R,6aS,8R,10aS)-1-[(3,5-difluorophenyl)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(1,3-thiazol-2-yl)acetamide
N-[(2S,3S,6R)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)oxan-3-yl]pyridine-2-carboxamide
N-[(2R,3S,6S)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)oxan-3-yl]pyridine-2-carboxamide
2-[(3S,6aS,8R,10aS)-1-[(3,5-difluorophenyl)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(1,3-thiazol-2-yl)acetamide
N-[(2R,3R,6R)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2S,3R,6R)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2R,3R,6S)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)oxan-3-yl]pyridine-2-carboxamide
N-[(2R,3S,6R)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2R,3S,6R)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide
N-[(2S,3R,6R)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide
N-[(2S,3S,6R)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide
2-[(3R,6aR,8S,10aR)-1-[(3,5-difluorophenyl)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3R,6aR,8R,10aR)-1-[(3,5-difluorophenyl)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
4-[(3aS,4R,9bS)-1-[1,3-benzodioxol-5-yl(oxo)methyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
4-[(3aR,4S,9bR)-1-[1,3-benzodioxol-5-yl(oxo)methyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
1-[(1R)-2-[(3-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-propanone
N-[(2S,3R,6S)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2S,3S,6S)-6-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2S,3R,6S)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide
N-[(2R,3R,6R)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide
N-[(2R,3S,6S)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide
N-[(2S,3S,6S)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide
N-[(2R,3R,6S)-6-[2-[(3-chlorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide
2-[(3R,6aS,8S,10aS)-1-[(3,5-difluorophenyl)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3S,6aR,8S,10aR)-1-[(3,5-difluorophenyl)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3S,6aS,8S,10aS)-1-[(3,5-difluorophenyl)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
2-[(3S,6aR,8R,10aR)-1-[(3,5-difluorophenyl)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-thiazolyl)acetamide
(2S,3S,3aR,9bR)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
4-[(3aR,4R,9bR)-1-[1,3-benzodioxol-5-yl(oxo)methyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
4-[(3aS,4S,9bS)-1-[1,3-benzodioxol-5-yl(oxo)methyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
1-[(1S)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
1-[(1S)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-propanone
1-[(1S)-2-[(3-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-propanone
1-[(1R)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
2-[(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)diazenyl]-3-oxo-N,3-diphenylpropanamide
Methyl 4-[3-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-1-(2-methoxyethyl)-4,5-dioxopyrrolidin-2-yl]benzoate
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2-methyl-3-oxo-1-phenylpropyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] cyclohexa-1,4-diene-1-carboxylate
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] cyclohexa-2,5-diene-1-carboxylate
4,7-DI(4-Ethoxyphenyl)-6-phenyl-1,2,5-thiadiazolo(3,4-C)pyridine
BI-6901
BI 6901 is a potent, selective CCR10 antagonist (pIC50=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research[1].
SB-612111 (hydrochloride)
SB-612111 hydrochloride hydrochloride is a novel and potent opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki=0.33 nM). SB-612111 hydrochloride exhibits selectivity for μ-,?κ- and?δ-receptors with Ki values of?57.6 nM, 160.5 nM and 2109 nM, respecticely. SB-612111 hydrochloride effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model[1].